GRAIL is trading at $162.00, up 5.14%, as coverage links the rise to upcoming Galleri presentations and FDA review.
- On October 5, GRAIL announced it will present NHS-Galleri and PATHFINDER 2 findings at medical conferences, including the October 6–8 EDCC.
- A September 23 FDA advisory panel vote favored Galleri’s potential benefits, but FDA approval is not guaranteed.
- Broad indexes are modestly higher; available coverage points to company-specific developments as the stronger explanation for the rally.